An interventional study of LX103 Injection in X-linked Retinoschisis, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to male participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to evaluate the safety and efficacy of LX103 treatment of X-linked retinoschisis. This study will enroll subjects aged ≥ 6 years old to receive a single unilateral intravitreal (IVT) injection of LX103 to evaluate its safety and efficacy.
19 studies on the registry are indexed under Retinoschisis; 5 are open to participants now.
This study's planned enrollment of 12 is below the median of 19 across 12 interventional studies indexed under Retinoschisis.
Browse Retinoschisis studies →Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 182 studies on the registry; 108 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Potential doses: 5E10 vg, 0.1 mL/eye/dose (low dose) 1E11 vg, 0.05 mL/eye/dose (high dose)
Genetic: LX103 Injection
Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
Incidence of adverse events (AEs)
Incidence of adverse events (AEs) within 24 weeks of LX103 intravitreal injection at different doses
Time frame: 24 weeks
Incidence of serious adverse events (SAEs)
Incidence of serious adverse events (SAEs) within 24 weeks of LX103 intravitreal injection at different doses
Time frame: 24 weeks
Mean change from baseline in BCVA (LogMAR) in the study eye
ETDRS visual acuity charts will be used to assess BCVA
Time frame: 24 weeks, 52 weeks
Mean change from baseline in central subfield thickness (CST) in the study eye
Mean change of CST measured using Optical Coherence Tomography (OCT)
Time frame: 24 weeks, 52 weeks
Change from baseline in Electroretinogram (ERG) parameters in the study eye
Change in dark-adapted 3.0 B-wave amplitude (μV)
Time frame: 24 weeks, 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Aug 2024, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine →